How Soon After Injection Does Wegovy Start Working?

Does Wegovy do anything straight away, or is the first few weeks just waiting?

Semaglutide does not sit inert after the injection. It binds to GLP-1 receptors involved in appetite signalling and gastric emptying within hours, and pharmacokinetic data show it reaches steady measurable concentrations in the blood over the first few days. What this means practically is that some people notice reduced appetite or a feeling of fullness arriving more quickly at meals during the first week, not dramatically, but perceptibly.

What most people do not notice in the first two to four weeks is significant weight loss. The 0.25 mg starting dose exists specifically to let your digestive system adjust; it is not the dose that drives substantial fat loss. Think of it as the body learning to work with the medicine before the medicine gets to work at full strength. The titration schedule (moving up through doses roughly every four weeks, as directed by your prescriber) is designed to reduce nausea while gradually delivering more of the therapeutic effect.

So if you are on week two and the scales look the same, that is not a failure. It is exactly what the schedule anticipates. The fuller picture of Wegovy's timeline makes more sense once you understand where each dose sits in the overall titration arc. For the pharmacological detail on how semaglutide acts in the body, the NHS semaglutide medicines page is a clear starting point.

When do most people start to see weight loss they can actually measure?

The honest answer is: it varies, but the pattern from clinical trials gives a useful frame. In the STEP 1 trial (68 weeks, involving adults with obesity given semaglutide 2.4 mg alongside lifestyle support) weight reduction accumulated steadily from around week four onwards, with the most rapid phase of loss typically falling between weeks eight and thirty-two as maintenance doses were reached. The average reduction across participants was around 15% of body weight by the end of the study.

In practice, people starting Wegovy through a private service often report that the first noticeable change is not the number on the scales but a shift in appetite, smaller portions feeling satisfying, less interest in snacking between meals, or simply not finishing a plate that previously would have been easy to clear. This appetite change is the mechanism working. Weight loss follows as the energy deficit accumulates over weeks.

A few practical factors influence individual timing: how much physical activity you are doing alongside treatment, how closely you are following the dietary guidance from your prescriber, and whether you experience significant nausea early on (which can itself temporarily affect food intake in ways that are not always comfortable). The detailed breakdown of what drives the pace of response is worth reading if you want to understand which variables actually matter.

For context on how Wegovy compares with tirzepatide (Mounjaro) on this timeline, the weight-loss treatment overview walks through both options clearly.

What if nothing seems to be happening, how do you know the pen is working?

This is a question our prescribers hear regularly, and it usually comes up around weeks two to six. A few things are worth checking first. Injection technique matters: the needle must reach the subcutaneous tissue (the fatty layer beneath the skin), not just the skin surface. Rotating injection sites (abdomen, thigh, upper arm) and ensuring the pen clicks correctly on each use are the basics. If you are seeing bent needles, incomplete doses or other equipment issues, the troubleshooting guide for Wegovy pen problems covers the most common causes.

If technique is sound and you are still seeing no change at all after six to eight weeks at a therapeutic dose, that is the kind of pattern worth raising with your prescriber. It is also worth remembering that some people respond more slowly than others for reasons that are not fully predictable in advance. Clinical guidance from NICE's appraisal of semaglutide for weight management (TA875) notes that continuing treatment should be reviewed if less than 5% weight loss is seen after six months on the maintenance dose, so there is a formal check-point built into the clinical pathway, not an open-ended commitment to wait indefinitely.

Semaglutide works through the same GLP-1 pathway as the diabetes medicine in this overview of semaglutide-based treatments, though the doses and licensed indications differ. Understanding the shared mechanism can help clarify why the timeline behaves the way it does.

Does the timing differ for the higher Wegovy doses approved more recently?

The MHRA approved a 7.2 mg maintenance dose of Wegovy in 2026, and a dedicated single-dose 7.2 mg pen followed in April 2026. Trials at this higher dose reported average weight loss of around 20.7% over 72 weeks, a meaningful step up from the 2.4 mg figure. The timeline to get there, however, is still governed by the same titration principle: treatment starts at 0.25 mg and increases gradually, so the body still needs several months to reach and settle at the highest dose.

The practical implication is that even with higher ceiling doses now available, the first eight to twelve weeks remain largely about adjustment rather than peak effect. People starting on Wegovy should think in quarters rather than weeks. The full Wegovy treatment guide covers the current licensed doses and what the titration schedule looks like across the full course.

If cost is a factor in deciding which treatment to start, the cost context page for Wegovy explains what private pricing typically covers and why the prescription and clinical review are part of that picture, not extras. And if you would like to see whether you are clinically suitable for Wegovy, check your eligibility with our prescribers, consultations are free, reviewed the same day by a real clinician, and there is no obligation to proceed.